Women With Parkinson’s May Face Higher Alzheimer’s-Related Brain Changes

Women With Parkinson’s Disease Show Higher Amyloid Plaque Burden Linked to Alzheimer’s, New Research Suggests

New research presented in 2026 suggests a potential sex-based difference in how Parkinson’s disease affects the brain, particularly in relation to Alzheimer’s disease pathology. Women living with Parkinson’s disease may be more likely than men to develop higher levels of amyloid beta plaques, a key biological marker associated with Alzheimer’s disease.

The findings, reported through medical news coverage and reviewed by health professionals, highlight an important area of ongoing research into neurodegenerative diseases and how they overlap. Parkinson’s disease and Alzheimer’s disease are both progressive brain disorders that primarily affect older adults, and they often occur together. However, scientists are still working to understand why some individuals experience more severe overlapping brain changes than others.

This article summarizes the findings, explains and outlines the current limitations of the research.

What the Researchers Studied

Researchers analyzed autopsy data from 230 individuals who had confirmed Parkinson’s disease. Because the diagnosis was confirmed after death, scientists were able to directly examine brain tissue for signs of disease-related changes.

The main focus of the study was amyloid beta plaques. These plaques are abnormal protein deposits in the brain that are strongly associated with Alzheimer’s disease. High levels of these plaques are considered a hallmark feature of Alzheimer’s pathology.

The researchers wanted to know whether there were differences between men and women with Parkinson’s disease in terms of how much amyloid buildup appeared in their brains.

Key Findings

The results showed a clear difference between sexes:

• Women with Parkinson’s disease were more than twice as likely as men to have high levels of amyloid beta plaques.
• About 57 percent of women showed a high plaque burden.
• Around 40 percent of men showed the same level of plaque accumulation.

These differences remained even after adjusting for other factors such as age and genetics.

Despite this significant difference in brain pathology, researchers found something unexpected.

There were no meaningful differences between men and women in:

• Rates of Alzheimer’s dementia diagnosis
• Performance on cognitive testing

This means that although women had more biological markers linked to Alzheimer’s disease, it did not clearly translate into worse measured cognitive outcomes in this dataset.

What the Findings May Mean

The findings suggest that women with Parkinson’s disease may be more biologically susceptible to Alzheimer’s-related brain changes, specifically amyloid plaque accumulation.

Researchers believe this could indicate that sex-based biological differences influence how neurodegenerative diseases develop and interact in the brain.

However, the disconnect between higher plaque levels and the absence of measurable cognitive decline differences raises important questions. It is possible that:

• The sample size was not large enough to detect subtle cognitive differences
• Other protective or compensatory brain mechanisms may exist in women
• Parkinson’s disease may interact with amyloid pathology differently than Alzheimer’s disease alone

Scientists emphasized that more research is needed before drawing firm conclusions.

Expert Interpretation

According to the study lead, Dr. Driver-Dunckley, the expectation would normally be that higher amyloid plaque burden leads to worse cognitive outcomes. However, this pattern was not clearly observed in this study.

She noted that larger studies may be necessary to detect more subtle effects on cognition and disease progression.

Researchers also emphasized the importance of continued investigation into how Parkinson’s disease interacts with Alzheimer’s-related changes, especially across sex differences.

Why This Research Matters

Understanding the relationship between Parkinson’s disease and Alzheimer’s disease is increasingly important as populations age worldwide. Both conditions are more common in older adults and can significantly impact memory, movement, and overall quality of life.

If women are more likely to develop Alzheimer’s-related brain changes in the context of Parkinson’s disease, this could eventually influence:

• Early screening approaches
• Personalized treatment strategies
• Risk assessment models
• Clinical trial design for neurodegenerative diseases

However, it is important to stress that these findings are still preliminary.

Limitations of the Study

Like all medical research, this study has limitations that should be considered:

• The data came from autopsies, meaning results reflect past disease progression rather than real-time tracking
• Cognitive outcomes were measured retrospectively, not longitudinally
• The study size, while meaningful, may not capture smaller subgroup differences
• Findings presented at medical conferences are not yet fully peer-reviewed

Because of these limitations, the results should be interpreted cautiously.

What Happens Next

Researchers plan to conduct larger clinicopathological studies to confirm whether the observed differences are consistent across broader populations.

Future research may also explore:

• Hormonal or genetic factors that influence amyloid buildup
• How Parkinson’s medications might interact with Alzheimer’s pathology
• Why higher plaque burden does not always match cognitive decline in this group

These next steps will help clarify whether sex-specific treatment approaches may eventually be needed.

Conclusion

This 2026 research adds to growing evidence that neurodegenerative diseases are complex and may affect men and women differently. Women with Parkinson’s disease appear more likely to show higher levels of amyloid beta plaques, a key marker of Alzheimer’s disease. However, this did not clearly translate into worse cognitive performance in the current study.

While the findings are important, they remain preliminary. More research is needed before drawing conclusions about diagnosis, treatment, or prognosis.

For now, the study highlights the importance of continued investigation into how Parkinson’s disease and Alzheimer’s disease interact, and how biological sex may influence brain health outcomes.

Source

• European Academy of Neurology meeting, Geneva, June 2026

Disclaimer

This article is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Scientific findings described here are based on preliminary research presented at a medical meeting and may not yet be peer-reviewed. Individual health conditions vary, and anyone with concerns about Parkinson’s disease, Alzheimer’s disease, or cognitive health should consult a qualified healthcare professional for personalized medical guidance.